Regeneron Pharmaceuticals
REGNNASDAQVelociSuite antibody discovery and genetics-enabled target selection
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
REGN filings on EDGAR →Cash & investments
$17.82B
at June 30, 2026 (10-Q)
Quarterly operating burn
No burn
operating cash flow positive, Jan–Jun 2026
Cash runway
—
not a runway: funded by operations
Shares outstanding
94.0M
cover page of the latest filing
Read from REGN's XBRL financial data; latest filing July 30, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
OLYMPIA-1: Odronextamab in Previously untreated follicular lymphoma — primary completion
2028-02-07
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pozelimab + cemdisiran PNH: Pozelimab and cemdisiran in Paroxysmal nocturnal haemoglobinuria — primary completion
2030-01-18
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Dupilumab paediatric EoE: Dupilumab in Eosinophilic oesophagitis in children — primary completion
2028-06-19
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Dupixent | multiple type 2 inflammatory diseases | Approved | Not disclosed | ▼ |
| Linvoseltamab | multiple myeloma | NDA/BLA Filed | Not disclosed | ▼ |
| Odronextamab | B-cell lymphomas | Phase 3 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium REGN analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you